Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) Meeting Abstract
| Authors: | Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A. D.; Parnis, F.; Knox, J.; Cattan, S.; Yau, T. C.; Lougheed, J.; Milwee, S.; El-Khoueiry, A.; Cheng, A. L.; Meyer, T.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 223s |
| Language: | English |
| ACCESSION: | WOS:000442916001664 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.4088 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4088 -- Source: Wos |
